Replimune (REPL) Other Non-Current Liabilities (2018 - 2026)
Replimune (REPL) posted Other Non-Current Liabilities of $455000.0 for Q1 2026, down 34.34% sequentially from $693000.0 in Q4 2025, and down 51.65% YoY from $941000.0 in Q1 2025.
Replimune (REPL) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Replimune has reported Other Non-Current Liabilities for 5 years, with the latest figure at $455000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 51.65% year-over-year to $455000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $455000.0 (down 51.65% YoY) and the FY2026 annual result came in at $455000.0, down 51.65% from the prior year.
- Other Non-Current Liabilities eased to $455000.0 in Q1 2026 per REPL's latest filing, from $693000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $1.3 million in Q4 2024 and troughed at $455000.0 in Q1 2026.
- A 4-year average of $762307.7 and a median of $786000.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Other Non-Current Liabilities soared 66.53% in 2024, then plunged 51.65% in 2026.
- Over 4 years, Other Non-Current Liabilities stood at $793000.0 in 2023, then soared by 59.65% to $1.3 million in 2024, then plunged by 45.26% to $693000.0 in 2025, then tumbled by 34.34% to $455000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $455000.0, $693000.0, and $941000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 455,000.00 |
| Dec 31, 2025 | 693,000.00 |
| Sep 30, 2025 | 941,000.00 |
| Jun 30, 2025 | 941,000.00 |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 786,000.00 |
| Jun 30, 2024 | 786,000.00 |
| Mar 31, 2024 | 786,000.00 |
| Dec 31, 2023 | 793,000.00 |
| Sep 30, 2023 | 472,000.00 |
| Jun 30, 2023 | 578,000.00 |
| Mar 31, 2023 | 472,000.00 |
| Jun 30, 2018 | 7.09 Mn |
| Mar 31, 2018 | 1.64 Mn |